Revenue
No reported data
Polaryx Therapeutics, Inc. (PLYX)
Price—Loading quote
Net income
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $6.3M | $2.8M |
| Operating expenses | $7.8M | $4.4M |
| Operating income | −$7.8M | −$4.4M |
| Net income | −$9.0M | −$30.4M |
| Basic EPSper diluted share | -$0.20 | -$0.89 |
| Diluted EPSper diluted share | -$0.20 | -$0.89 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | Mstone Partners Healthcare Ltd +1Director,TenPercentOwner | BuyCommon Stock · indirect | 88.5K | $4.07 | $360.0K | 24.23M |
| Feb 18, 2026Form 4 | Landis G. MichaelChief Financial Officer | BuyCommon Stock | 2.9K | $2.79 | $8.0K | 228.2K |